Researchers continue to excited about this new drug, a groundbreaking dual agonist showing remarkable outcomes in early trials for size management. It works by impacting both systems: GLP-1 and GIP, which , when activated , assist regulate cravings and enhance metabolism . Initial findings suggest substantial size loss and potential advantages for